神卓方治疗糖尿病肾脏病伴大量白蛋白尿的随机对照试验方案
本研究为24周、随机、多中心、双盲、双模拟、对照临床试验,拟纳入120例18至80岁、24小时尿蛋白0.5至3克且血肌酐≤133微摩尔/升的糖尿病肾脏病伴大量白蛋白尿患者,比较神卓方与厄贝沙坦的疗效与安全性,主要终点为24小时尿蛋白自基线至第24周的变化。
要点
- 神卓方对比厄贝沙坦治疗DKD大量白蛋白尿,主要终点为24周24小时尿蛋白变化。
- 纳入标准:年龄18至80岁,24小时尿蛋白0.5至3克,血肌酐≤133微摩尔/升。
- 设计为24周随机双盲双模拟多中心对照试验,计划纳入120例患者。
核心结论
- 本研究旨在提供神卓方相对厄贝沙坦治疗糖尿病肾脏病伴大量白蛋白尿患者疗效与安全性的初步证据。
研究设计与样本
- 本研究为24周、随机、多中心、双盲、双模拟、对照临床试验,计划纳入120例糖尿病肾脏病患者。
- 纳入患者年龄18至80岁,24小时尿蛋白介于0.5克至3克,血肌酐≤133微摩尔/升(1.5毫克/分升)。
- 干预为神卓方对比厄贝沙坦,主要终点为24小时尿蛋白自基线至第24周的变化。
关键数值与推荐
- 主要终点为24小时尿蛋白自基线至第24周的变化。
- 次要终点包括血肌酐、估算肾小球滤过率、中医症状、尿白蛋白排泄率等,并评估安全性。
- 试验注册于中国临床试验注册中心,注册号ChiCTR-ICR-15006311,注册日期2015年4月15日。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diabetic kidney disease (DKD) is a serious complication associated with diabetes mellitus and can cause end-stage renal disease (ESRD). Traditional Chinese medicine (TCM) is widely used in China to treat DKD, and in particular microalbuminuria and macroalbuminuria. This study will address the efficacy and safety of Shenzhuo Formula (SZF), a frequently prescribed TCM, in DKD patients with macroalbuminuria. METHODS/DESIGN: This study is a 24-week, randomized, multi-center, double-blinded, double-dummy, controlled, clinical trial that will include 120 DKD patients aged 18 to 80 years old with a 24-h urinary protein (24-h UP) level of between 0.5 g and 3 g and serum creatinine (SCr) ≤ 133 μmol/L (1.5 mg/dL) and compare SZF to irbesartan. The 24-h UP change from baseline to week 24 will represent the primary endpoint with secondary endpoints including SCr, estimated glomerular filtration rate (eGFR), TCM symptoms, urinary albumin excretion rate (UAER), etc. Safety assessments will also be evaluated. DISCUSSION: This study will provide initial evidence regarding the efficacy and safety of SZF relative to irbesartan in the treatment of DKD patients with macroalbuminuria. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ID: ChiCTR-ICR-15006311 . Registered on 15 April 2015.
引用
- Zhao XM, Zhang Y, He XH, et al. Chinese herbal medicine Shenzhuo Formula treatment in patients with macroalbuminuria secondary to diabetic kidney disease: study protocol for a randomized controlled trial. Trials. 2018. PMID: 29587863. doi:10.1186/s13063-018-2573-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。